['open angle glaucoma', 'ocular hypertension']
['1 drop of 0.375% syl040012 (bamosiran)', '1 drop of 0.750% syl040012 (bamosiran)', '1 drop of 1.125% syl040012 (bamosiran)', '1 drop of 1.5% syl040012 (bamosiran)', '1 drop of 0.5 % timolol maleate']

        Inclusion Criteria:

          -  Patients older than 18 years of either sex

          -  Good or fair general health as assessed by the investigator.

          -  Signed informed consent prior to any clinical trial-related procedures

          -  Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT)

          -  Post-washout mean IOP above target range

          -  BCVA 1.0 logMAR or better by ETDRS in each eye (equivalent to 20/200)

          -  Stable visual field

          -  Central corneal thickness 480-620 μm

          -  Shaffer gonioscopic grade of ≥ 3 (in at least 3 quadrants) in both eyes

        Exclusion Criteria:

          -  Pregnant or breastfeeding females

          -  Females of childbearing potential not willing to use a medically acceptable
             contraceptive method

          -  Clinically significant systemic disease

          -  Changes of systemic medication that could have a substantial effect on IOP

          -  Known hypersensitivity to any component of the formulations

          -  Unable to comply with the clinical trial requirements

          -  Clinically significant abnormalities in laboratory tests

          -  Severe visual field defect

          -  Any secondary glaucoma

          -  Pseudoexfoliation or pigment dispersion component, history of angle closure or narrow
             angles.

          -  IOP ≥ 35 mm Hg in any eye

          -  Previous non-laser glaucoma surgery or glaucoma laser procedures (e.g., laser
             trabeculoplasty) and refractive surgery

          -  Any ocular surgery or laser treatment, cataract extraction or ocular trauma within 6
             months prior to Baseline

          -  Evidence of ocular infection, inflammation, clinically significant blepharitis or
             conjunctivitis at baseline (Visit 0), or a history of herpes simplex keratitis

          -  Clinically significant ocular disease
      